REPL Replimune Group, Inc. stock chart & analysis

Conviction 4HealthcareScan · Fri, Nov 6, 2026

Mat hold

Replimune Group, Inc. (REPL) closed at $21.62 (+7.99%) on Nov 6, 2026. Its latest daily candle is a mat hold. Price is above its 50-day and above its 200-day moving average. RSI(14) 80, RS Rating 99, -1.4% from its 52-week high, +122.2% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

REPL$21.62+7.99%

ResistanceSupportVol 14Insider buyInsider sell

Loading chart…

Replimune Group, Inc.Biological Products, (No Diagnostic Substances)www.replimune.com ↗

Price21.62

Change+7.99%

Gap+0.15%

Rel volume1.55×

Avg volume3.19M

Avg $ vol52.44M

SMA 2014.79

SMA 5014.09

SMA 2009.64

Price vs 50+53.26%

Price vs 200+124.16%

MA stackbullish

50/200 cross—

Supertrendup · 16.84

RSI (14)80

MACD hist0.92

MACD crossbull · 9d

Stoch %K / %D97 / 93

ADX (14)38

+DI / −DI46 / 11

RSI divergence—

MACD divergenceBullish

ATR %5.88%

ADR %8.00%

52w high21.90

52w low1.50

From 52w high-1.35%

Above 52w low+1340.00%

New 52w highYes

SqueezeOff

Bollinger width102.93%

%B0.95

Donchian pos97.37%

Donchian high21.90

Donchian low10.67

AVWAP (52w high)21.18

vs AVWAP high+1.97%

AVWAP (52w low)8.16

vs AVWAP low+164.64%

OBV trendUp

Chaikin MF (20)0.33

Today vs 20d1.55×

Avg vol (14d)3.88M

Avg vol (20d)3.19M

Avg $ vol (20d)52.44M

Market cap2.05B

RS Rating99 / 99

RS 3m (vs SPY)+62.88%

RS 6m (vs SPY)+546.18%

RS line new highYes

Trend template8/8

Technical rank99.3

1 week+22.66%

1 month+65.64%

3 months+58.01%

6 months+546.71%

1 year+140.80%

YTD+122.22%

P/E-6.52

P/B10.00

P/S—

P/FCF-7.20

EPS-3.38

Div yield—

ROE-153.31%

ROA-83.95%

Debt/Eq0.49

Current7.11

EV/EBITDA-5.81

Gross margin—

Net margin—

Rev growth—

EPS growth-26.95%

Price target21.86

Target upside1.20%

Analyst ratingBuy

Institutional104.27%

Ent. value1.84B

Revenue—

Net income-57.12M

Gross profit—

Free cash flow-284.57M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out82.57M

Employees479

ListedFri, Jul 20, 2018

Free float62.65M

Float %75.9%

Short interest—

Days to cover—

Short volume52.0%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$0.54 vs −$0.70

Last surprise+22.9% beat

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank99.3 / 100

Group rank23 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmMat hold

Financials as of Wed, Sep 30, 2026 · quarterly.

REPL technical analysis

Trend

REPL is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 53.3% above the 50-day ($14.09) and 124.2% above the 200-day ($9.64). ADX(14) at 38 points to a strong, established trend. It meets 8 of 8 trend-template criteria.

Momentum

RSI(14) is 80, in overbought territory. MACD crossed above its signal line 9 sessions ago. A bullish MACD divergence is in place. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.

Volume and volatility

Volume on the latest session ran 1.6× its 20-day average. It trades about $52.4M a day on average. ATR(14) is $1.27, 5.9% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.33) shows accumulation.

Key levels

The 52-week range is $1.50 to $21.90; price is 1.4% below the high and 1340.0% above the low. The VWAP anchored at the 52-week high is $21.18, below price.

Performance

REPL returned +22.7% (1 week), +65.6% (1 month), +58.0% (3 months), +546.7% (6 months), +140.8% (1 year), +122.2% (year to date).

About Replimune Group, Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Biological Products, (No Diagnostic Substances) · Listed 2018 · 479 employees

Insider activity

SEC Form 4 transactions in REPL · open-market 1 buy · 6 sells

Insider	Side	Shares	Value	Traded	Filed
Dhingra Kapil Director · Common Stock · 2026-11-02	Exercise	43.17K	$76K	2026-11-02	2026-11-03
Dhingra Kapil Director · Common Stock · 2026-11-02	Sell	21.5K	$409K	2026-11-02	2026-11-03
Dhingra Kapil Director · Stock Option (right to buy) · 2026-11-02	Exercise	43.17K	—	2026-11-02	2026-11-03
Astley-Sparke Philip Director · Common Stock · 2026-08-20	Gift	50K	—	2026-08-20	2026-08-24
Hill Emily Luisa Chief Financial Officer · Common Stock · 2026-08-17	Sell	9.26K	$132K	2026-08-17	2026-08-19
Hill Emily Luisa Chief Financial Officer · Common Stock · 2026-08-10	Sell	11.45K	$148K	2026-08-10	2026-08-12
Patel Sushil Chief Executive Officer · Common Stock · 2026-08-10	Sell	39.34K	$510K	2026-08-10	2026-08-12
Schwendenman Andrew Chief Accounting Officer · Common Stock · 2026-08-10	Sell	7.63K	$99K	2026-08-10	2026-08-12
Xynos Konstantinos Chief Medical Officer · Common Stock · 2026-08-10	Sell	11.45K	$148K	2026-08-10	2026-08-12
BAKER BROS. ADVISORS LP Director · 2026 $0.0001 Prefunded Warrants · 2026-08-11	Buy	126.39K	$1.5M	2026-08-11	2026-08-11

SEC filings

EDGAR filings in REPL · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.